The duration of follow-up after first stroke attack of anti-BP180 positive patients (7.0 ± 2.94 years) was significantly shorter than that of anti-BP180 negative patients (10.4 ± 6.05 years; P < 0.001), further supporting that younger stroke patients with shorter duration after first attack are more likely to develop BP antibodies. The gene discussed is COL17A1; the disease is Stroke.